{"disease":{"id":"multidrug-resistant-tuberculosis","name":"multidrug resistant tuberculosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05081401","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04421495","title":"Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":608,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT01424670","title":"Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04484129","title":"MDR-TB Close Contacts Tracing in China (TCCT Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT03604848","title":"NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","phase":"NA","overall_status":"UNKNOWN","enrollment_count":488,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT03867136","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT02454205","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT02727582","title":"Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT03942354","title":"Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial","phase":"","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT07393438","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT04717908","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","phase":"NA","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT07191834","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wuhan Pulmonary Hospital","has_results":false},{"nct_id":"NCT07170800","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT01859923","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT01856634","title":"Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}